Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2019

View Archived Issues

Novel transgenic mouse model of memory impairment

Primary results show improvements in clinical outcomes in TOURMALINE-AL1 phase III study

'Love hormone' plays role in bones, fat

DNA circles drive neuroblastomas

Phase III study begins for first-line treatment of NSCLC with TAK-788

First functional oocytes derived from granulosa cells

Amgen identifies new KRAS G12C inhibitors

New eIF-2-alpha kinase GCN2 inhibitors discovered at RAPT Therapeutics

Idorsia Pharmaceuticals patents lysophosphatidic acid receptor 1 antagonists

Corcept Therapeutics presents glucocorticoid receptor antagonists

RAN protein is ALS target

RBM17 splicing factor maintains leukemia stem cell function in acute myeloid leukemia

Patient enrollment ongoing in phase I study of PF-06940434

Juventas Cell Therapy presents phase I data for CNCT-19 in acute lymphoblastic leukemia

RALA as a novel therapeutic target in triple-negative breast cancer

Pfizer initiates phase I study of PF-07062119

Agios Pharmaceuticals starts recruitment in phase III study of AG-881

Dosing of inarigivir stopped in phase II CATALYST program

Promising overall response and duration of response in phase IIa trial of PTX-200 in breast cancer

Roche and Genentech patent describes YAP1/TEAD interaction inhibitors

Baergic Bio enters agreements with AstraZeneca and Cincinnati Children's Hospital for AZD-7325

Clinical hold on PR-001 study in neuronopathic Gaucher's disease removed